



UNITED STATES OF AMERICA  
FEDERAL TRADE COMMISSION  
WASHINGTON, D.C. 20580

Office of the Secretary

May 3, 2002

Daniel Tripodi, Ph.D.  
The Sage Group, Inc.  
245 Route 22 West, Suite 304  
Bridgewater, NJ 08807

Re: Baxter International Inc.  
Docket No. C-3726

Dear Dr. Tripodi:

This letter is to inform you that, pursuant to Paragraph II.C.8. of the above-referenced order, the Commission has approved your April 2, 2002, request that the Commission extend the period for twelve (12) months, through May 8, 2003, during which NABI may continue to seek to obtain all necessary FDA approvals of its own to manufacture Baxter's Factor VIII Inhibitor Treatments.

By direction of the Commission.

A handwritten signature in black ink that reads "Donald S. Clark".

Donald S. Clark  
Secretary

cc: Michael Sennett, Esq.  
Bell, Boyd & Lloyd  
Three First National Plaza  
70 West Madison Street, Suite 3300  
Chicago, IL 60602-4207